Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline Review, H1 2015

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline Review, H1 2015', provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Plaque Psoriasis (Psoriasis Vulgaris) Overview 9

Therapeutics Development 10

Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris)-Overview 10

Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris)-Comparative Analysis 11

Plaque Psoriasis (Psoriasis Vulgaris)-Therapeutics under Development by Companies 12

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Plaque Psoriasis (Psoriasis Vulgaris)-Products under Development by Companies 19

Plaque Psoriasis (Psoriasis Vulgaris)-Companies Involved in Therapeutics Development 24

Almirall, S.A. 24

Amgen Inc. 25

Avesthagen Limited 26

Avexxin AS 27

Biocon Limited 28

Biotie Therapies Corp. 29

Can-Fite BioPharma Ltd. 30

Celltrion, Inc. 31

Circassia Pharmaceuticals plc 32

Coherus BioSciences, Inc. 33

Creabilis SA 34

Delenex Therapeutics AG 35

Dermira Inc. 36

Epirus Biopharmaceuticals, Inc. 37

Forward Pharma A/S 38

Galectin Therapeutics, Inc. 39

Genor BioPharma Co., Ltd. 40

Idera Pharmaceuticals, Inc. 41

Invion Limited 42

Johnson & Johnson 43

Kadmon Corporation, LLC 44

Kineta, Inc. 45

Kyowa Hakko Kirin Co., Ltd. 46

LEO Pharma A/S 47

Lipidor AB 48

Mabion SA 49

Maruho Co., Ltd. 50

Momenta Pharmaceuticals, Inc. 51

Oncobiologics, Inc. 52

Pfizer Inc. 53

Promius Pharma, LLC 54

Protalix BioTherapeutics, Inc. 55

Provectus Biopharmaceuticals, Inc. 56

R-Tech Ueno, Ltd. 57

TetraLogic Pharmaceuticals 58

Therapeutic Proteins International, LLC 59

UCB S.A. 60

Valeant Pharmaceuticals International, Inc. 61

XBiotech USA, Inc. 62

Plaque Psoriasis (Psoriasis Vulgaris)-Therapeutics Assessment 63

Assessment by Monotherapy Products 63

Assessment by Combination Products 64

Assessment by Target 65

Assessment by Mechanism of Action 68

Assessment by Route of Administration 70

Assessment by Molecule Type 72

Drug Profiles 74

(betamethasone dipropionate + bexarotene)-Drug Profile 74

(calcipotriene + betamethasone dipropionate)-Drug Profile 75

(calcipotriene + betamethasone)-Drug Profile 77

adalimumab biosimilar-Drug Profile 78

adalimumab biosimilar-Drug Profile 79

adalimumab biosimilar-Drug Profile 80

adalimumab biosimilar-Drug Profile 81

adalimumab biosimilar-Drug Profile 82

adalimumab biosimilar-Drug Profile 83

adalimumab biosimilar-Drug Profile 84

adalimumab biosimilar-Drug Profile 85

adalimumab biosimilar-Drug Profile 86

adalimumab biosimilar-Drug Profile 87

AM-001-Drug Profile 88

ASKP-1240-Drug Profile 89

AVX-001-Drug Profile 90

betamethasone + maxacalcitol-Drug Profile 91

bimekizumab-Drug Profile 92

brodalumab-Drug Profile 93

BTT-1023-Drug Profile 95

calcipotriene-Drug Profile 97

CF-101-Drug Profile 98

CIR-001-Drug Profile 100

CT-327-Drug Profile 101

dalazatide-Drug Profile 103

DFD-01-Drug Profile 105

DFD-06-Drug Profile 106

dimethyl fumarate-Drug Profile 107

DLX-105-Drug Profile 108

DRM-02-Drug Profile 110

etanercept biosimilar-Drug Profile 111

etanercept biosimilar-Drug Profile 112

etanercept biosimilar-Drug Profile 113

etanercept biosimilar-Drug Profile 114

etanercept biosimilar-Drug Profile 115

GK-664S-Drug Profile 116

GR-MD-02-Drug Profile 117

guselkumab-Drug Profile 120

IDP-118-Drug Profile 123

IMO-8400-Drug Profile 124

infliximab biosimilar-Drug Profile 126

infliximab biosimilar-Drug Profile 128

infliximab biosimilar-Drug Profile 129

infliximab biosimilar-Drug Profile 130

infliximab biosimilar-Drug Profile 131

INV-103-Drug Profile 132

KD-025-Drug Profile 134

LEO-32731-Drug Profile 136

LP-0113-Drug Profile 137

M-801801-Drug Profile 138

MOL-4239-Drug Profile 139

MOL-4249-Drug Profile 140

pefcalcitol-Drug Profile 141

PF-04965842-Drug Profile 142

PF-06700841-Drug Profile 143

PH-10-Drug Profile 144

RA-18C3-Drug Profile 146

RTU-1096-Drug Profile 148

SHP-141-Drug Profile 149

tofacitinib-Drug Profile 151

toreforant-Drug Profile 155

ustekinumab-Drug Profile 157

Plaque Psoriasis (Psoriasis Vulgaris)-Recent Pipeline Updates 160

Plaque Psoriasis (Psoriasis Vulgaris)-Dormant Projects 216

Plaque Psoriasis (Psoriasis Vulgaris)-Discontinued Products 221

Plaque Psoriasis (Psoriasis Vulgaris)-Product Development Milestones 223

Featured News & Press Releases 223

Appendix 230

Methodology 230

Coverage 230

Secondary Research 230

Primary Research 230

Expert Panel Validation 230

Contact Us 230

Disclaimer 231

List of Tables

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2015 14

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris)-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Development by Companies, H1 2015 (Contd..3) 26

Products under Development by Companies, H1 2015 (Contd..4) 27

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Almirall, S.A., H1 2015 28

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Amgen Inc., H1 2015 29

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Avesthagen Limited, H1 2015 30

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Avexxin AS, H1 2015 31

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Biocon Limited, H1 2015 32

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Biotie Therapies Corp., H1 2015 33

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Can-Fite BioPharma Ltd., H1 2015 34

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Celltrion, Inc., H1 2015 35

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Circassia Pharmaceuticals plc, H1 2015 36

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Coherus BioSciences, Inc., H1 2015 37

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Creabilis SA, H1 2015 38

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Delenex Therapeutics AG, H1 2015 39

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Dermira Inc., H1 2015 40

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 41

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Forward Pharma A/S, H1 2015 42

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Galectin Therapeutics, Inc., H1 2015 43

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Genor BioPharma Co., Ltd., H1 2015 44

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Idera Pharmaceuticals, Inc., H1 2015 45

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Invion Limited, H1 2015 46

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Johnson & Johnson, H1 2015 47

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Kadmon Corporation, LLC, H1 2015 48

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Kineta, Inc., H1 2015 49

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 50

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by LEO Pharma A/S, H1 2015 51

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Lipidor AB, H1 2015 52

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Mabion SA, H1 2015 53

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Maruho Co., Ltd., H1 2015 54

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 55

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Oncobiologics, Inc., H1 2015 56

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Pfizer Inc., H1 2015 57

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Promius Pharma, LLC, H1 2015 58

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Protalix BioTherapeutics, Inc., H1 2015 59

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 60

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by R-Tech Ueno, Ltd., H1 2015 61

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by TetraLogic Pharmaceuticals, H1 2015 62

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Therapeutic Proteins International, LLC, H1 2015 63

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by UCB S.A., H1 2015 64

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 65

Plaque Psoriasis (Psoriasis Vulgaris)-Pipeline by XBiotech USA, Inc., H1 2015 66

Assessment by Monotherapy Products, H1 2015 67

Assessment by Combination Products, H1 2015 68

Number of Products by Stage and Target, H1 2015 70

Number of Products by Stage and Mechanism of Action, H1 2015 73

Number of Products by Stage and Route of Administration, H1 2015 75

Number of Products by Stage and Molecule Type, H1 2015 77

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics-Recent Pipeline Updates, H1 2015 164

Plaque Psoriasis (Psoriasis Vulgaris)-Dormant Projects, H1 2015 220

Plaque Psoriasis (Psoriasis Vulgaris)-Dormant Projects (Contd..1), H1 2015 221

Plaque Psoriasis (Psoriasis Vulgaris)-Dormant Projects (Contd..2), H1 2015 222

Plaque Psoriasis (Psoriasis Vulgaris)-Dormant Projects (Contd..3), H1 2015 223

Plaque Psoriasis (Psoriasis Vulgaris)-Dormant Projects (Contd..4), H1 2015 224

Plaque Psoriasis (Psoriasis Vulgaris)-Discontinued Products, H1 2015 225

Plaque Psoriasis (Psoriasis Vulgaris)-Discontinued Products (Contd..1), H1 2015 226

List of Figures

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2015 14

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris)-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Products, H1 2015 22

Assessment by Monotherapy Products, H1 2015 67

Assessment by Combination Products, H1 2015 68

Number of Products by Top 10 Targets, H1 2015 69

Number of Products by Stage and Top 10 Targets, H1 2015 69

Number of Products by Top 10 Mechanism of Actions, H1 2015 72

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 72

Number of Products by Top 10 Routes of Administration, H1 2015 74

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 75

Number of Products by Top 10 Molecule Types, H1 2015 76

Number of Products by Stage and Top 10 Molecule Types, H1 2015 77

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Almirall, S.A.

Amgen Inc.

Avesthagen Limited

Avexxin AS

Biocon Limited

Biotie Therapies Corp.

Can-Fite BioPharma Ltd.

Celltrion, Inc.

Circassia Pharmaceuticals plc

Coherus BioSciences, Inc.

Creabilis SA

Delenex Therapeutics AG

Dermira Inc.

Epirus Biopharmaceuticals, Inc.

Forward Pharma A/S

Galectin Therapeutics, Inc.

Genor BioPharma Co., Ltd.

Idera Pharmaceuticals, Inc.

Invion Limited

Johnson & Johnson

Kadmon Corporation, LLC

Kineta, Inc.

Kyowa Hakko Kirin Co., Ltd.

LEO Pharma A/S

Lipidor AB

Mabion SA

Maruho Co., Ltd.

Momenta Pharmaceuticals, Inc.

Oncobiologics, Inc.

Pfizer Inc.

Promius Pharma, LLC

Protalix BioTherapeutics, Inc.

Provectus Biopharmaceuticals, Inc.

R-Tech Ueno, Ltd.

TetraLogic Pharmaceuticals

Therapeutic Proteins International, LLC

UCB S.A.

Valeant Pharmaceuticals International, Inc.

XBiotech USA, Inc.

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutic Products under Development, Key Players in Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Overview, Plaque Psoriasis (Psoriasis Vulgaris) Pipeline, Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com